Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVS 
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: CRVS (4-star) is a STRONG-BUY. BUY since 78 days. Simulated Profits (74.02%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.33
1 Year Target Price $15.33
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1468.14% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 601.19M USD | Price to earnings Ratio - | 1Y Target Price 15.33 |
Price to earnings Ratio - | 1Y Target Price 15.33 | ||
Volume (30-day avg) 6 | Beta 0.64 | 52 Weeks Range 2.54 - 9.32 | Updated Date 12/3/2025 |
52 Weeks Range 2.54 - 9.32 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.13 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.87% | Return on Equity (TTM) -35.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 620154766 | Price to Sales(TTM) - |
Enterprise Value 620154766 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 74681872 | Shares Floating 58112205 |
Shares Outstanding 74681872 | Shares Floating 58112205 | ||
Percent Insiders 3.95 | Percent Institutions 57.17 |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies. Founded in 2014, Corvus has focused on targets in the adenosine pathway and has advanced several candidates into clinical development.
Core Business Areas
- Immuno-Oncology Drug Development: Corvus Pharmaceuticals focuses on discovering and developing small molecule and antibody therapies that target the immune system to treat cancer. Their primary focus is on the adenosine pathway.
Leadership and Structure
Dr. Richard A. Miller is the CEO. The company has a board of directors with expertise in oncology drug development and finance. The organizational structure is typical for a small biotech company, with research, clinical development, and business development functions.
Top Products and Market Share
Key Offerings
- CPI-818: An ITK inhibitor in Phase 2 clinical trials for T cell lymphomas. Competitors include companies developing therapies for T-cell lymphomas, though CPI-818 has a novel mechanism. Market share data is unavailable as it is still in development.
- Soquelitin (CPI-444): A small molecule inhibitor of adenosine A2A receptor in Phase 1/1b clinical trials. Competitors include companies developing similar adenosine antagonists such as Arcus Biosciences. Market share data is unavailable as it is still in development.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, with significant investment and competition. Companies are focused on novel targets and combination therapies.
Positioning
Corvus is positioned as an innovator in the adenosine pathway targeting immuno-oncology. Their competitive advantage lies in their specific targets and the potential for combination therapies.
Total Addressable Market (TAM)
The immuno-oncology market is projected to reach hundreds of billions of dollars. Corvus is targeting specific segments within this larger market. The potential TAM for each of their products depends on clinical trial success and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (adenosine pathway)
- Experienced management team
- Proprietary technology
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Single area of focus
- Relatively small company
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Regulatory approvals
- Combination therapies
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding challenges
- Patent challenges
Competitors and Market Share
Key Competitors
- ARCT
- MRTX
- NKTR
Competitive Landscape
Corvus competes with both large pharmaceutical companies and smaller biotech companies. Its advantage lies in its novel targets, but it faces challenges due to limited resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial progress and securing funding.
Future Projections: Future growth depends on clinical trial success and potential commercialization or partnering opportunities. Analyst estimates vary.
Recent Initiatives: Focus on advancing CPI-818 and Soquelitin through clinical trials and exploring combination therapies.
Summary
Corvus Pharmaceuticals is a clinical-stage biotech company focused on immuno-oncology with a novel approach targeting the adenosine pathway. Their success hinges on positive clinical trial results for CPI-818 and Soquelitin, requiring partnerships and significant funding. They face stiff competition and regulatory hurdles. Their strengths are the unique therapeutic targets and experienced leadership, while weaknesses include limited resources and dependence on clinical outcomes. They must capitalize on opportunities through partnerships and expand into new indications.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Corvus Pharmaceuticals Inc. website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Future projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.